Benjamin A. Weinberg
YOU?
Author Swipe
View article: Correlates and Detection of Digital Health Literacy in Patients With Colorectal Carcinoma or Non-Hodgkin Lymphoma: Cross-Sectional Study
Correlates and Detection of Digital Health Literacy in Patients With Colorectal Carcinoma or Non-Hodgkin Lymphoma: Cross-Sectional Study Open
Background Cutting-edge oncology care often depends on patients’ ability to use rapidly evolving health technology. Digital health literacy (DHL; the capacity to understand health-related information with electronic media) is an emerging, …
View article: Obesity reprograms the normal pancreas and pancreatic cancer microbiome in mice and humans
Obesity reprograms the normal pancreas and pancreatic cancer microbiome in mice and humans Open
Introduction Pancreatic ductal adenocarcinoma (PDAC) is an aggressive form of pancreatic cancer, with overall 5-year survival rates of about 8%. Obesity (and underlying metabolic dysfunction) is estimated to account for up to 50% of all PD…
View article: A phase II single-arm study of combination pembrolizumab and olaparib in the treatment of patients with advanced biliary tract cancer.
A phase II single-arm study of combination pembrolizumab and olaparib in the treatment of patients with advanced biliary tract cancer. Open
Effective second-line treatment for advanced biliary tract cancer (BTC) remains an unmet need. BTC often presents with homologous recombination repair (HRR) pathway deficiencies and IDH1/IDH2 mutations which suggest responsiveness to Poly …
View article: Novel origin of replication for environmentally isolated <i>Pantoea</i> strain enables expression of heterologous proteins, pathways and products
Novel origin of replication for environmentally isolated <i>Pantoea</i> strain enables expression of heterologous proteins, pathways and products Open
Plasmids isolated or characterized from environmental samples serve as a resource that can be used to develop genetic tools for characterizing recently isolated or less-studied microbes. In this report, we leveraged sequences from a previo…
View article: Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion–Positive Cancer
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion–Positive Cancer Open
Zenocutuzumab showed efficacy in patients with advanced NRG1 fusion-positive cancer, notably NSCLC and pancreatic cancer, with mainly low-grade adverse events. (Funded by Merus; eNRGy ClinicalTrials.gov number, NCT02912949.).
View article: Longitudinal Circulating Tumor Cell Collection, Culture, and Characterization in Pancreatic Adenocarcinomas
Longitudinal Circulating Tumor Cell Collection, Culture, and Characterization in Pancreatic Adenocarcinomas Open
Background/Objectives: Pancreatic adenocarcinoma (PDAC) remains one of the most lethal cancers, with limited advancements in treatment efficacy due to high rates of chemoresistance. Circulating tumor cells (CTCs) derived from liquid biopsi…
View article: Rethinking the rise of early-onset gastrointestinal cancers: a call to action
Rethinking the rise of early-onset gastrointestinal cancers: a call to action Open
Since the early 1990s, there has been a dramatic rise in gastrointestinal cancers diagnosed in patients under age 50 for reasons that remain poorly understood. The most significant change has been the increase in incidence rates of early-o…
View article: Comprehensive characterization of <i>MCL‐1</i> in patients with colorectal cancer: Expression, molecular profiles, and outcomes
Comprehensive characterization of <i>MCL‐1</i> in patients with colorectal cancer: Expression, molecular profiles, and outcomes Open
Myeloid cell leukemia 1 (MCL‐1) is a member of the B‐cell lymphoma 2 protein family and has anti‐apoptotic functions. Deregulation of MCL‐1 has been reported in several cancers, including lung and breast cancer. In the present study, the a…
View article: Supplementary Table 6 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Supplementary Table 6 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer Open
Supplementary Table 6
View article: Supplementary Table 2 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Supplementary Table 2 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer Open
Supplementary Table 2
View article: Supplementary Table 4 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Supplementary Table 4 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer Open
Supplementary Table 4
View article: Supplementary Table 5 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Supplementary Table 5 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer Open
Supplementary Table 5
View article: Supplementary Table 9 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Supplementary Table 9 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer Open
Supplementary Table 9
View article: Supplementary Table 7 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Supplementary Table 7 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer Open
Supplementary Table 7
View article: Supplementary Table 8 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Supplementary Table 8 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer Open
Supplementary Table 8
View article: Supplementary Table 10 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Supplementary Table 10 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer Open
Supplementary Table 10
View article: Supplementary Table 3 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Supplementary Table 3 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer Open
Supplementary Table 3
View article: Supplementary Figures 1 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Supplementary Figures 1 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer Open
Supplementary Figures
View article: Supplementary Methods 1 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Supplementary Methods 1 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer Open
Supplementary Methods
View article: Data from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Data from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer Open
Purpose:Transcriptional profiling of pancreatic cancers has defined two main transcriptional subtypes: classical and basal. Initial data suggest shorter survival for patients with basal tumors and differing treatment sensitivity to FOLFIRI…
View article: Supplementary Table 1 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Supplementary Table 1 from Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer Open
Supplementary Table 1
View article: Role of <i>CD47</i> gene expression in colorectal cancer: a comprehensive molecular profiling study
Role of <i>CD47</i> gene expression in colorectal cancer: a comprehensive molecular profiling study Open
Background In patients with colorectal cancer (CRC), the therapeutic effects of conventional immune checkpoint inhibitors targeting the adaptive immune system are largely limited to those with microsatellite instability-high tumors. Meanwh…
View article: Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer Open
Purpose: Transcriptional profiling of pancreatic cancers has defined two main transcriptional subtypes: classical and basal. Initial data suggest shorter survival for patients with basal tumors and differing treatment sensitivity to FOLFIR…
View article: Comparative molecular profiling of pancreatic ductal adenocarcinoma of the head versus body and tail
Comparative molecular profiling of pancreatic ductal adenocarcinoma of the head versus body and tail Open
Pancreatic ductal adenocarcinoma (PDAC) of the head (H) and body/tail (B/T) differ in embryonic origin, cell composition, blood supply, lymphatic and venous drainage, and innervation. We aimed to compare the molecular and tumor immune micr…
View article: <i>CCR5</i> and <i>CCL5</i> gene expression in colorectal cancer: comprehensive profiling and clinical value
<i>CCR5</i> and <i>CCL5</i> gene expression in colorectal cancer: comprehensive profiling and clinical value Open
Background The C-C motif chemokine receptor 5 (CCR5)/C-C motif chemokine ligand 5 (CCL5) axis plays a major role in colorectal cancer (CRC). We aimed to characterize the molecular features associated with CCR5 / CCL5 expression in CRC and …
View article: 716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or gastroesophageal cancer
716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or gastroesophageal cancer Open
Background Despite advances made in management of patients with HER2-driven solid tumors, unmet need remains for novel approaches to improve patient outcomes. BDC-1001 is an ISAC consisting of a trastuzumab biosimilar conjugated to a propr…